STXS

#3784
Stereotaxis, Inc. Common Stock
1.3 9 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.39
1.41
Jahresspanne
1.24
2.34
Tagesänderung
-0.71%
Monatliche Änderung
+1.46%
6 month change
-35.50%
Jahresänderung
-33.17%
Vorheriger Schlusskurs
1.4 0
Open
1.4 0
Tief
1.3 9
Hoch
1.4 1
Volumen
111
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Stereotaxis, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Stereotaxis, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Stereotaxis, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Stereotaxis, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Stereotaxis, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Stereotaxis, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Stereotaxis, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Stereotaxis, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Stereotaxis, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Stereotaxis, Inc. annual report, FY2025
10-K

Stereotaxis, Inc. current report, Q2 FY2026

Full document

Stereotaxis, Inc. Form 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Shareholders held by Stereotaxis, Inc. on May 14, 2026. The company is incorporated in Delaware and its common stock trades on NYSE American LLC under the symbol STXS.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.

Material Changes and Voting Results

At the meeting, 79,183,920 votes were represented, constituting approximately 65.34% of the total outstanding voting power of 121,182,983 votes. The following proposals were approved:

  • Election of Directors: Three Class I directors were elected to serve until the 2029 Annual Meeting.
    • Mr. David Benfer: 52,225,420 votes for; 1,364,215 against.
    • Dr. Arun Menawat: 49,544,105 votes for; 4,050,991 against.
    • Dr. Myriam Curet: 52,711,903 votes for; 868,378 against.
  • Ratification of Auditors: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 (79,036,638 votes for; 112,633 against).
  • Executive Compensation: The advisory proposal to approve executive compensation was approved (52,143,334 votes for; 985,434 against).

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Verify the total voting power calculation, which includes 97,477,538 common shares and 23,705,445 votes from Series A Convertible Preferred Stock on an as-converted basis.
  • Note the significant number of broker non-votes (25,581,057) recorded for the director election and executive compensation proposals.
  • Confirm the tenure of the newly elected directors, who will serve until the 2029 Annual Meeting.
  • Review the fiscal year 2026 audit engagement with Ernst & Young LLP as ratified by shareholders.

Nachrichten